Figure 5.

Therapeutic treatment of miR-145-5p agomirs in TNBS-induced colitis mice. a. Colon lengths. b, Recovery of body weight. c, MPO activity of the colon. d, Serum FITC-dextran FD40. e-h, miR-145-5p agomirs upregulates CLDN8 by inhibiting the expression of SOX9. i, H&E and IHC staining for SOX9 in the colon tissues of colitic mice. j, Histological scores were assessed by H&E staining of colon tissues (Agomir group, n = 5; Agomir-control group, n = 5; Controls group, n = 5). Scale bars, 100 μm. All Data are shown as means ± SEM in (c), (d), (e), (f), (g) and (j). Student's t-test and one-way ANOVA were used for comparison, respectively. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 as compared with the control.